Effectiveness of Fixed-Dose Perindopril/Amlodipine on Clinic, Ambulatory and Self-Monitored Blood Pressure and Blood Pressure Variability: An Open-Label, Non Comparative Study in the General Practice

High Blood Pressure and Cardiovascular Prevention

Volumn 22, Issue 4, 2015, Pages 417-425

  Karpov, Yuri A ^a   Gorbunov, Vladimir M ^b   Deev, Alexander D ^b  

^a Federal State Institution Russian Cardiology Scientific and Industrial Complex   (Russian Federation)

^b NATIONAL MEDICAL RESEARCH CENTER FOR THERAPY AND PREVENTIVE MEDICINE   (Russian Federation)

Author keywords

ACE inhibitor; Arterial hypertension; Blood pressure variability; Calcium channel blocker; Fixed dose combination; Perindopril amlodipine

Indexed keywords

AMLODIPINE PLUS PERINDOPRIL; AMLODIPINE; AMLODIPINE, PERINDOPRIL DRUG COMBINATION; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG COMBINATION; PERINDOPRIL;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE VARIABILITY; CARDIOVASCULAR RISK; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART RATE; HOME MONITORING; HUMAN; HYPERTENSION; LEG EDEMA; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; SELF MONITORING; AGED; AMBULATORY CARE; BLOOD PRESSURE; CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECTS; GENERAL PRACTICE; MIDDLE AGED; MULTICENTER STUDY; OBSERVER VARIATION; PATHOPHYSIOLOGY; PREDICTIVE VALUE; REPRODUCIBILITY; RUSSIAN FEDERATION; TIME FACTOR; TREATMENT OUTCOME;

ADULT; AGED; AMLODIPINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CALCIUM CHANNEL BLOCKERS; DRUG COMBINATIONS; FEMALE; GENERAL PRACTICE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; OBSERVER VARIATION; OFFICE VISITS; PERINDOPRIL; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; RUSSIA; TIME FACTORS; TREATMENT OUTCOME;

EID: 84948963927     PISSN: 11209879     EISSN: 11791985     Source Type: Journal    
DOI: 10.1007/s40292-015-0117-0     Document Type: Article

References (44)

1. Mathers C, Stevens G, Mascarenhas M. Global health risks: mortality and burden of disease attributable to selected major risks. Geneva; 2009. http://www.who.int/healthinfo/global_burden_disease/GlobalHealthRisks_report_full.pdf.
2. Harmon L, Chilton RJ, Spellman C. Reducing cardiovascular events and end-organ damage in patients with hypertension: new considerations. Postgrad Med. 2011;123(2):7–17.
3. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of ESH and of ESC. Eur Heart J. 2013;34(28):2159–219.
4. Go AS, Bauman MA, King SMC, et al. An effective approach to high blood pressure control. A science advisory from AHA, ACC, and the Centers for Disease Control and Prevention. Hypertension. 2014;63(4):878–85.
5. James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–20.
6. Clement DL, De Buyzere ML, De Bacquer DA, et al. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. New Engl J Med. 2003;348:2407–15.
7. Dolan E, Stanton AV, Thom S, et al. Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients—an Anglo-Scandinavian cardiac outcomes trial substudy. J Hypertens. 2008;27:876–85.
8. Rothwell PM, Howard SC, Dolan E, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure and episodic hypertension. Lancet. 2010;375:895–905.
9. Oganov RG, Timofeev TN, Koltunov IE, et al. Epidemiology of hypertension in Russia. The results of 2003–2010 federal monitoring. Cardiovasc Ther Prev. 2011;10:9–13.
10. Dallongeville J, Banegas JR, Tubach F, et al., For the EURIKA Study. Survey of physicians’ practices in the control of cardiovascular risk factors: the EURIKA study. Eur J Prev Cardiol. 2012;19(3):541–50.
11. Prugger C, Keil U, Wellman J, et al., For the EUROASPIRE III. Blood pressure control and knowledge of target blood pressure in coronary patients across Europe: results from the EUROASPIRE III survey. J Hypertens. 2011;29(8):1641–8.
12. Bramlage P, Böhm M, Volpe M, et al., For the ISEARCH Study. A global perspective on blood pressure treatment and control in a referred cohort of hypertensive patients. J Clin Hypertens (Greenwich). 2010;12(9):666–77.
13. Tocci G, Ferrucci A, Pontremoli R, et al. Blood pressure levels and control in Italy: comprehensive analysis of clinical data from 2000–2005 and 2005–2011 hypertension surveys. J Hum Hypertens. 2015. doi:10.1038/jhh.2015.4.
14. Karpov YA, Deev AD, On behalf of the doctors participating in the program PRORYV. Uncontrolled hypertension—new opportunities in solving the problem of increasing the effectiveness of treatment. Kardiologija. 2012;2:29–35.
15. Russian Medical Society of Hypertension, Russian Scientific Society of Cardiology. Diagnosis and treatment of hypertension. Russian recommendations (fourth revision); 2010.
16. Longo D, Toffanin G, Garbelotto R, et al. Performance of the UA-787 oscillometric blood pressure monitor according to the European Society of Hypertension protocol. Blood Press Monit. 2003;8(2):91–5.
17. Rogoza AN, Nikolsky VP, Oshchepkova EV, et al. Ambulatory blood pressure monitoring in hypertension: methodological issues; 2005.
18. Rizzoni D, Castellano M, Muiesan ML. Beyond trough-to-peak ratio: a new index of the smoothness of the antihypertensive effect of a drug. High Blood Press. 1997;6:110–5.
19. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67–74.
20. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich). 2008;10(5):348–54.
21. Sever PS, Dahlof B, Poulter NR, et al., ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-BPLA): a multicenter randomized controlled trial. Lancet. 2005;366(9489):895–906.
22. Rodriguez-Granillo GA, Vos J, Bruining N, et al., Investigators of the EUROPA Study. Long-term effect of Perindopril on coronary atherosclerosis progression (from the PERindopril’s Prospective Effect on Coronary aTheroslerosis by Angiography and IntraVascular Ultrasound Evaluation [PERSPECTIVE] Study). Am J Cardiol. 2007;100(2):159–63.
23. Tropeano AI, Boutouyrie P, Pannier B, et al. Brachial pressure-independent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensives. Hypertension. 2006;48:80–6.
24. Williams B, Lacy PS, Thom SM, et al., CAFE Investigators, Anglo-Scandinavian Cardiac Outcomes Trial Investigators, CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes principal results of the conduit artery evaluation (CAFE) study. Circulation. 2006;113(9):1213–25.
25. Kobalava ZhD, Kotovskaya Y, Lukyanova L, et al. Combination therapy of hypertension fixed combination of perindopril arginine/amlodipine in clinical practice: the organization and the main results of the program KONSTANTA. Kardiologija. 2013;6:25.
26. Bahl VK, Jadhav UM, Thacker HP. Management of hypertension with the fixed combination of perindopril and amlodipine in daily clinical practice. Results from the STRONG prospective, observational, multicenter study. Am J Cardiovasc Drugs. 2009;9(3):135–42.
27. Hatala R, Bachanova K, Sidlo R, SYMBIO Investigators. SYMBIO: results of a longitudinal study of optimized blood pressure lowering therapy with fixed combination perindopril/amlodipine. J Hypertens. 2010;28:e98–9.
28. Karpov YA. Achieving the target blood pressure in patients with hypertension uncontrolled when translating from mono- or combination therapy for a fixed combination of an ACE inhibitor and a calcium antagonist. Arter Hypertens. 2012;18(6):484.
29. Boggia J, Li Y, Thijs L, et al. Prognostic accuracy of day vs. night ambulatory blood pressure: a cohort study. Lancet. 2007;370(9594):1219–29.
30. Fagard RH, Celis H, Thijs L, et al. Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension. 2008;51(1):55–61.
31. Bliziotis IA, Destounis A, Stergiou GS. Home versus ambulatory and office blood pressure in predicting target organ damage in hypertension: a systematic review and meta-analysis. J Hypertens. 2012;30(7):1289–99.
32. Stergiou G, Siontis KC, Ioannidis JP. Home blood pressure as a cardiovascular outcome predictor: it’s time to take this method seriously. Hypertension. 2010;55(6):1301–3.
33. Fagard RH, Van Den Broeke C, De Cort P. Prognostic significance of blood pressure measured in the office, at home and during ambulatory monitoring in older patients in general practice. J Hum Hypertens. 2005;19(10):801–7.
34. Mancia G, Facchetti R, Bombelli M, et al. Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. Hypertension. 2006;47(5):846–53.
35. Kobalava ZD, Kotovskaya IV, Lukyanova EA, On behalf of the participants in the program KONSTANTA. Combination therapy of hypertension with the fixed combination of perindopril arginine/amlodipine in clinical practice: the organization and the main results of the study. Kardiologija. 2013;53(6):25–34.
36. Schillaci G, Pucci G, Parati G. Blood pressure variability. An additional target for antihypertensive treatment. Hypertension. 2011;58:133–5.
37. Poulter NR. Blood pressure variability: a new challenge in blood pressure measurement. In: Bakris GL, Bertrand M, Blacher J, et al., editors. Improving management of hypertension: reconsidering efficacy assessment. Berlin: Springer Science; 2012. p. 35–46.
38. Mancia G. Short- and long-term blood pressure variability. Present and future. Hypertension. 2012;60(2):512–7.
39. Parati G, Bilo G. Calcium antagonist added to angiotensin receptor blocker: a recipe for reducing blood pressure variability? Evidence from day-to-day home blood pressure monitoring. Hypertension. 2012;59:1091–3.
40. Muntner P, Schimbo D, Tonelli M, Reynolds K, Arnett DK, Oparil S. The relationship between visit-to-visit variability in systolic blood pressure and all-cause mortality in the general population: findings from NHANES III, 1988 to 1994. Hypertension. 2011;57:160–6.
41. Matsui Y, O’Rourke MF, Hoshide S, et al. Combined effect of angiotensin II receptor blocker and either a calcium channel blocker or diuretic on day-by-day variability of home blood pressure. Hypertension. 2012;59:1132–8.
42. Matsumoto A, Satoh M, Kikuya M, et al. Day-to-day variability of blood pressure is associated with cognitive decline. The Ohasama study. Hypertension. 2014;63(6):1333–8.
43. Parati G, Ochoa J, Lombardi C, Bilo G. Assessment and management of blood-pressure variability. Nat Rev Cardiol. 2013;10:143–55.
44. Parati G, Omboni S, Rizzoni D, et al. Smoothness index: a new, reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension. J Hypertens. 1998;16:1685–91.